Today: 25 June 2026
Browse Category

BSE:504346 14 October 2025

Stock Market Today

  • BioMarin Pharmaceutical Q1 Earnings Compared to Therapeutics Peers
    June 25, 2026, 12:26 PM EDT. BioMarin Pharmaceutical (NASDAQ:BMRN) posted $766.2 million in Q1 revenue, a 2.8% increase year-on-year but slightly below analysts' expectations by 1.3%. Despite missing EPS estimates, BioMarin raised full-year guidance the most among 11 tracked therapeutics stocks, reflecting confidence fueled by its acquisition of Amicus Therapeutics and portfolio expansion. The therapeutics sector saw a 14.5% revenue beat against consensus, driven by advances in precision medicine and rare disease treatments. Moderna (NASDAQ:MRNA) led Q1 gains with a 260% revenue surge, outperforming expectations by 56%. BioMarin's shares advanced 3.8% post-report, trading at $57.57, marking resilience amid market headwinds including drug pricing scrutiny and regulatory uncertainties.

Latest News

MARA Stock Drops After Monday’s Jump, Bitcoin and Nasdaq Weakness Pressure AI Pivot Trade

MARA Holdings dips after AI bull call runs into share plan math

25 June 2026
MARA Holdings (NASDAQ:MARA) dropped 3.0% to $13.585 despite a bullish $24 target from Citizens, as investors weighed a shareholder-approved 18 million share increase to its equity plan—about 4.7% dilution risk—amid ongoing bitcoin exposure and a $1.26 billion Q1 net loss driven by crypto price swings.
Strategy (NASDAQ:MSTR) drops as STRC dividend pulls bitcoin funding

Strategy (NASDAQ:MSTR) drops as STRC dividend pulls bitcoin funding

25 June 2026
Strategy Inc (MSTR) stock fell 5.7% after raising $335.5 million in new shares but using only $34.9 million to buy bitcoin, with most funds boosting its USD reserve to $1.4 billion—enough to cover 14 months of STRC preferred dividends, as STRC traded 21% below par amid market focus on cash reserves over bitcoin buys.
Go toTop